Heron Therapeutics Inc Stock Price, News & Analysis

Heron Therapeutics (Nasdaq: HRTX) appointed Thomas Cusack to its Board of Directors effective October 27, 2025. His appointment was made pursuant to a Cooperation Agreement with Rubric Capital dated August 8, 2025. Cusack brings more than 20 years of experience in investment management and corporate finance, including service as a Managing Director at Starboard Value from 2011–2025, a fund cited with approximately $9 billion assets under management. His background includes roles in M&A at Barclays Capital and Lehman Brothers and a B.S. in Finance & Accounting from NYU Stern.

The company said the appointment will add governance and investment-management expertise to the board as Heron pursues its commercial-stage objectives.

Heron Therapeutics (Nasdaq: HRTX) will report third quarter 2025 financial results on Tuesday, November 4, 2025, and will host a conference call and live webcast at 8:30 a.m. ET to discuss results and recent business highlights.

Participants can join by phone via a registration link that provides dial-in details; callers are encouraged to dial in 15 minutes early. The webcast will be available in the Investor Relations section at www.herontx.com. An archive of the teleconference and webcast will be available on the website for 60 days after the call.

Heron Therapeutics (Nasdaq: HRTX) has implemented a Section 382 Rights Plan to protect its valuable $1.37 billion in net operating loss (NOL) carryforwards. The plan, effective August 14, 2025, aims to prevent an ownership change that could limit the company's ability to utilize these tax benefits.

The Rights Plan restricts any single investor or group from acquiring 4.99% or more of Heron's outstanding common stock. This one-year plan aligns with the company's Note Purchase Agreement with Rubric Capital Management and was unanimously approved by the Board of Directors to safeguard potential tax benefits as the company pursues its growth strategy.

Heron Therapeutics (NASDAQ: HRTX) has completed a comprehensive capital restructuring to enhance financial flexibility and reduce debt. The multi-faceted refinancing includes: a $110 million senior credit facility from Hercules Capital (with additional $40 million available in milestone-based tranches), retirement of existing convertible notes through $125 million cash repayment and $25 million stock conversion, issuance of $35 million new convertible notes, and a $27.7 million private placement.

The restructuring aims to eliminate near-term debt maturities and provide working capital for commercial and development initiatives. The transactions, initiated on August 8, 2025, are expected to close on August 12, 2025.

Heron Therapeutics (NASDAQ:HRTX) reported strong Q2 2025 financial results with total net revenue of $37.2 million, a 3.3% increase year-over-year. The company's Acute Care franchise showed impressive growth of 55.5% year-over-year in Q2 2025.

Key highlights include ZYNRELEF unit demand growth of 6.3% and APONVIE unit demand growth of 19% in Q2 compared to Q1 2025. The company completed a capital restructuring, reducing total debt from $175M to $145M and extending maturities to 2030.

Heron raised its 2025 Adjusted EBITDA guidance to $9.0-$13.0 million from $4.0-$12.0 million, while reaffirming net revenue guidance of $153-$163 million. The company ended Q2 with $40.6 million in cash and equivalents.

Heron Therapeutics (Nasdaq: HRTX) has rescheduled its second quarter 2025 financial results release and conference call to Friday, August 8, 2025, at 8:30 a.m. ET, moved up from the previously scheduled date of August 11, 2025.

The company will discuss Q2 2025 financial results and recent business highlights during the call. Participants are encouraged to dial in fifteen minutes before the start time using the provided registration link. The presentation will also be available via webcast on Heron's website, with a replay accessible for 60 days following the call.

Heron Therapeutics (NASDAQ: HRTX), a commercial-stage biotechnology company, has scheduled its second quarter 2025 financial results conference call for Monday, August 11, 2025, at 4:30 p.m. ET. The company will discuss Q2 2025 financial performance and recent business highlights during the call.

Participants can access the conference call through a registration link and are encouraged to dial in fifteen minutes before the scheduled start time. A webcast will be available through Heron's Investor Relations website section, with a 60-day replay period following the call.

Heron Therapeutics (NASDAQ: HRTX) reported strong Q1 2025 financial results with net revenue of $38.9 million, up 12.2% year-over-year, and record Adjusted EBITDA of $6.2 million. The growth was primarily driven by their acute care franchise, which increased 89.4%, with ZYNRELEF sales growing 60.4%. The company reached a settlement with Mylan regarding CINVANTI and APONVIE patent litigations, setting market entry for June 1, 2032. Heron raised its 2025 Adjusted EBITDA guidance to $4-12M from $0-8M, while maintaining net revenue guidance of $153-163M. The company's cash position stood at $50.7M as of March 31, 2025. Notable developments include the implementation of Non-Opioid Policy for Pain Relief and successful launch of the VAN for ZYNRELEF, with plans for a Prefilled Syringe launch in early 2027.

Heron Therapeutics (NASDAQ: HRTX) has reached a settlement agreement with Mylan Pharmaceuticals, a Viatris company, regarding patent litigation for CINVANTI® and APONVIE® injectable emulsions. The settlement grants Mylan a license to market generic versions of both drugs in the United States starting June 1, 2032, or earlier under certain circumstances.

The patent litigations were initiated by Heron in September 2023 and January 2024 after Mylan sought FDA approval for generic versions before the Heron Patents' expiration in 2035. Both companies will file for dismissal of the pending litigations with the U.S. District Court for the District of Delaware.